date:Apr 30, 2014
Ganeden Biotech has been issued U.S. patent No. 8,697,055 B2 that protects the use of all Bacillus coagulans probiotic strains, including the companys GanedenBC30, in coffee, tea and cereal applications.
This patent goes a long way toward supporting our partners in their quest to launch new brands and revolutionize existing ones, said Andy Lefkowitz, chief executive officer of Cleveland-based Ganeden Biotech.
Spore-forming probiotic organisms such as GanedenBC30 (Bacillus coagulans GBI-30, 608